Thomas Lunt

Thomas’ patents work spans the fields of life sciences, tech and telecoms. His recent cases include AstraZeneca v Glenmark (the most recent appellate decision concerning preliminary injunctions in the pharmaceutical field, and the most recent concerning plausibility), Akebia v Fibrogen (a leading case on the approach to sufficiency of functional claims), and Sandoz, Teva v BMS (the first appellate decision on plausibility following G2/21). He is experienced in economic disputes relating to patents, including FRAND proceedings and damages inquiries such as Dr Reddy’s, NHS England & ors v Warner-Lambert (described by The Lawyer as “potentially the most complicated follow-on damages inquiry ever heard before the Patents Court”).

Additionally, Thomas is a contributing author to Terrell on the Law of Patents, editing the chapters on construction and plausibility. In 2025, Thomas was called to the Irish bar.

Thomas maintains an active trade marks practice and has worked on cases across diverse sectors including beverages, luxury personal goods, and medical devices. The great majority of his trade mark work reached settlement before trial. In addition to his experience before the High Court, he represents clients unled before the UK IPO.

2019-2020: 12-month pupillage at Three New Square to Miles Copeland, Jeremy Heald, Joe Delaney, Stuart Baran and Geoff Pritchard.

2017-2018: BPTC at BPP Birmingham: Outstanding; 1st in cohort.

2016-2017: GDL at BPP Birmingham: Distinction.

2012-2016: MChem Chemistry at Lincoln College, Oxford: 1st class. Part-II thesis in soft chemistry of solid- state crystalline compounds from the cerium oxychalcogenide series.